CheckMate 227 three-year update: Nivolumab plus ipilimumab versus chemo as first-line treatment for advanced NSCLC

Bookmark and Share
Published: 2 Jun 2020
Views: 512
Rating:
Save
Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, USA

Prof Suresh Ramalingam speaks to ecancer about results from the three-year update from the CheckMate 227 study into nivolumab plus ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC) presented at the 2020 ASCO Virtual Meeting.

He reports that the three year survival rate for patients with PD-L1 expression greater than 1% and treated with nivolumab plus ipilimumab was 33% compared to 22% for the chemotherapy group.

Prof Ramalingam also reports that in the PD-L1 expression less than 1% group the three year survival rate with nivolumab plus ipilimumab was 34% compared to 15% for the chemotherapy group.

He also highlights that the durability of the responses was around 3 to 4 times longer in the nivolumab plus ipilimumab groups compared to the chemotherapy groups.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.